According to Future Market Insights, the CAGR of nearly 4% during the forecast period (2017-2026), in terms of volume. Over 4000,000 Mn units of dry powder inhaler are pegged to be sold across the globe by 2026-end.
Challenges Regarding Varying Characteristics of Dry Powder Inhalers to Pave Opportunities for Medical Device Manufacturers: Regulatory pressures and changes in drug delivery. According to the World Health Organization (WHO), nearly 300 Mn people worldwide are affected by asthma, and approximately 240 Mn from the chronic obstructive pulmonary disease (COPD). Over half of these patients suffer from the combined use of dry powder inhalers for the treatment of their disease. These devices have proven to be effective and reliable in their delivery. Some inhalers are associated with dose-delivery, performances at varying airflows, and fine particle fraction content. These characteristics may vary with regard to powder formulations, creating the need for fine tuning of the device or powder formulation or both combined for optimal performance. The requirement is particularly high in micro-dosing dry powder inhalers, which in turn is paving opportunities for medical device manufacturers in terms of innovation and advancements.
Growing adoption of unhealthy lifestyle, increasing geriatric population, and growing air pollution levels. Filling prevalence of various respiratory disorders are key factors driving the expansion of the global dry powder inhaler market, In addition, the government growth in the near future. However, the fact that dry powder inhalers are not moisture-resistant remains a major challenge for manufacturers, as the medicine loses its properties. Availability of effective alternative inhalers and dry pumps are expected. Lack of awareness regarding these devices in low-income & underdeveloped countries may further hinder the market growth to a certain extent.
North America wants to continue to be the most lucrative region for growth of the dry powder inhaler market. Dry powder inhaler sales in the region will register the fastest expansion through 2026. Asia-Pacific excluding Japan (APEJ) is expected to be the second largest dry powder inhaler market. Hospital pharmacies intends to continue to deliver the leading distribution channel for dry powder inhalers, with sales pegged to surpass 150,000 Mn units by 2026-end.
Dry powder inhalers will continue to be the largest application in the treatment of asthma, followed by chronic obstructive pulmonary disease. In addition, sales of dry powder inhalers for application in the treatment of asthma and pulmonary arterial hypertension are slated to exhibit a parallel growth through 2026.
Leading companies in the global dry powder inhaler market are focusing on the development of new generation products. These market players are making huge investments in R & D activities associated with novel device architectures, particle engineering, and powder formulations. Development of improved particle properties, along with efficient inhaler designs. Key market participants in the report include Vectura Group Plc, MannKind Corporation, Chiesi Farmaceutici SpA, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Limited, Cipla Ltd., Novartis AG, GlaxoSmithKline Plc, 3M Company, and AstraZeneca Plc.
A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/REP-GB-5150